Teva Pharmaceutical Industries Limited (NYSE: TEVA) Stock Competitors & Peer Comparison
See TEVA's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TEVA and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TEVA | $41.31 | -0.46% | 48.1B | 14.09 | $2.93 | N/A |
| TAK | $19.61 | -0.31% | 62.4B | 14.10 | $1.39 | +3.59% |
| HLN | $10.14 | +0.10% | 44.6B | 20.77 | $0.49 | +1.95% |
| ZTS | $79.59 | +0.26% | 32.9B | 12.09 | $6.58 | +2.62% |
| VTRS | $18.26 | -2.12% | 21B | 7.25 | $2.52 | +2.64% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.49 | -0.25% | 11.7B | 22.15 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $13.08 | +0.08% | 10.9B | 27.85 | $0.47 | +0.64% |
| ALKS | $42.97 | +4.25% | 7.2B | 45.23 | $0.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
TEVA vs TAK Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, TAK has a market cap of 62.4B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while TAK trades at $19.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas TAK's P/E ratio is 14.10. In terms of profitability, TEVA's ROE is +0.09%, compared to TAK's ROE of +0.02%. Regarding short-term risk, TEVA is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check TAK's competition here
Haleon plc (NYSE: HLN)
TEVA vs HLN Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, HLN has a market cap of 44.6B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while HLN trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas HLN's P/E ratio is 20.77. In terms of profitability, TEVA's ROE is +0.09%, compared to HLN's ROE of +0.10%. Regarding short-term risk, TEVA is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
TEVA vs ZTS Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ZTS has a market cap of 32.9B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ZTS trades at $79.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ZTS's P/E ratio is 12.09. In terms of profitability, TEVA's ROE is +0.09%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, TEVA is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
TEVA vs VTRS Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, VTRS has a market cap of 21B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while VTRS trades at $18.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas VTRS's P/E ratio is 7.25. In terms of profitability, TEVA's ROE is +0.09%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, TEVA is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
TEVA vs ITCI Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ITCI's P/E ratio is -180.64. In terms of profitability, TEVA's ROE is +0.09%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, TEVA is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
TEVA vs ELAN Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ELAN has a market cap of 11.7B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ELAN trades at $23.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ELAN's P/E ratio is 22.15. In terms of profitability, TEVA's ROE is +0.09%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, TEVA is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
TEVA vs CTLT Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas CTLT's P/E ratio is -27.84. In terms of profitability, TEVA's ROE is +0.09%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, TEVA is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
TEVA vs RDY Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, RDY has a market cap of 10.9B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while RDY trades at $13.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas RDY's P/E ratio is 27.85. In terms of profitability, TEVA's ROE is +0.09%, compared to RDY's ROE of +0.09%. Regarding short-term risk, TEVA is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
TEVA vs ALKS Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ALKS has a market cap of 7.2B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ALKS trades at $42.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ALKS's P/E ratio is 45.23. In terms of profitability, TEVA's ROE is +0.09%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, TEVA is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
TEVA vs LNTH Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while LNTH trades at $99.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas LNTH's P/E ratio is 16.79. In terms of profitability, TEVA's ROE is +0.09%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, TEVA is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
TEVA vs AMRX Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, AMRX has a market cap of 6.2B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while AMRX trades at $19.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas AMRX's P/E ratio is 21.51. In terms of profitability, TEVA's ROE is +0.09%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, TEVA is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check AMRX's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
TEVA vs RGC Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, RGC has a market cap of 5B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while RGC trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas RGC's P/E ratio is -1005.00. In terms of profitability, TEVA's ROE is +0.09%, compared to RGC's ROE of -1.61%. Regarding short-term risk, TEVA is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check RGC's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
TEVA vs INDV Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, INDV has a market cap of 4.2B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while INDV trades at $33.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas INDV's P/E ratio is 9.28. In terms of profitability, TEVA's ROE is +0.09%, compared to INDV's ROE of -2.16%. Regarding short-term risk, TEVA is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check INDV's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
TEVA vs HCM Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while HCM trades at $14.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas HCM's P/E ratio is 137.14. In terms of profitability, TEVA's ROE is +0.09%, compared to HCM's ROE of +0.01%. Regarding short-term risk, TEVA is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check HCM's competition here
Alvotech (NASDAQ: ALVOW)
TEVA vs ALVOW Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ALVOW has a market cap of 2.4B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ALVOW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ALVOW's P/E ratio is 37.90. In terms of profitability, TEVA's ROE is +0.09%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, TEVA is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ALVOW's competition here
Bausch Health Companies Inc. (NYSE: BHC)
TEVA vs BHC Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while BHC trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas BHC's P/E ratio is 1.62. In terms of profitability, TEVA's ROE is +0.09%, compared to BHC's ROE of +0.89%. Regarding short-term risk, TEVA is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check BHC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
TEVA vs SUPN Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, SUPN has a market cap of 2.3B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while SUPN trades at $39.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas SUPN's P/E ratio is 13.02. In terms of profitability, TEVA's ROE is +0.09%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, TEVA is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check SUPN's competition here
Perrigo Company plc (NYSE: PRGO)
TEVA vs PRGO Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, PRGO has a market cap of 2.2B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while PRGO trades at $16.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas PRGO's P/E ratio is 6.44. In terms of profitability, TEVA's ROE is +0.09%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, TEVA is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check PRGO's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
TEVA vs DCPH Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas DCPH's P/E ratio is -11.58. In terms of profitability, TEVA's ROE is +0.09%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, TEVA is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
TEVA vs AVDL Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, TEVA's ROE is +0.09%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, TEVA is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
TEVA vs EMBCV Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas EMBCV's P/E ratio is N/A. In terms of profitability, TEVA's ROE is +0.09%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, TEVA is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
TEVA vs DVAX Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas DVAX's P/E ratio is -41.89. In terms of profitability, TEVA's ROE is +0.09%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, TEVA is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
TEVA vs ALVO Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ALVO trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ALVO's P/E ratio is -8.53. In terms of profitability, TEVA's ROE is +0.09%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, TEVA is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ALVO's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
TEVA vs TRLV Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, TRLV has a market cap of 1.7B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while TRLV trades at $10.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas TRLV's P/E ratio is -4.18. In terms of profitability, TEVA's ROE is +0.09%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, TEVA is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check TRLV's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
TEVA vs ANIP Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ANIP trades at $72.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ANIP's P/E ratio is 8.84. In terms of profitability, TEVA's ROE is +0.09%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, TEVA is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
TEVA vs TARO Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas TARO's P/E ratio is 30.05. In terms of profitability, TEVA's ROE is +0.09%, compared to TARO's ROE of +0.03%. Regarding short-term risk, TEVA is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
TEVA vs PAHC Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while PAHC trades at $39.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas PAHC's P/E ratio is 13.42. In terms of profitability, TEVA's ROE is +0.09%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, TEVA is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check PAHC's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
TEVA vs PCRX Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, PCRX has a market cap of 1.4B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while PCRX trades at $36.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas PCRX's P/E ratio is 13.98. In terms of profitability, TEVA's ROE is +0.09%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, TEVA is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check PCRX's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
TEVA vs ETON Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ETON has a market cap of 1.4B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ETON trades at $49.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ETON's P/E ratio is 129.50. In terms of profitability, TEVA's ROE is +0.09%, compared to ETON's ROE of +0.40%. Regarding short-term risk, TEVA is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
TEVA vs CRON Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while CRON trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas CRON's P/E ratio is 16.64. In terms of profitability, TEVA's ROE is +0.09%, compared to CRON's ROE of +0.06%. Regarding short-term risk, TEVA is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
TEVA vs AMPH Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while AMPH trades at $26.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas AMPH's P/E ratio is 8.92. In terms of profitability, TEVA's ROE is +0.09%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, TEVA is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
TEVA vs HROW Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, HROW has a market cap of 1B. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while HROW trades at $27.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas HROW's P/E ratio is -27.96. In terms of profitability, TEVA's ROE is +0.09%, compared to HROW's ROE of -1.04%. Regarding short-term risk, TEVA is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
TEVA vs PETQ Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas PETQ's P/E ratio is 83.73. In terms of profitability, TEVA's ROE is +0.09%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, TEVA is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
TEVA vs COLL Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, COLL has a market cap of 749.1M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while COLL trades at $23.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas COLL's P/E ratio is 2.89. In terms of profitability, TEVA's ROE is +0.09%, compared to COLL's ROE of +0.16%. Regarding short-term risk, TEVA is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
TEVA vs IRWD Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, IRWD has a market cap of 584.9M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while IRWD trades at $3.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas IRWD's P/E ratio is 4.54. In terms of profitability, TEVA's ROE is +0.09%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, TEVA is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
TEVA vs BDSI Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas BDSI's P/E ratio is 6.82. In terms of profitability, TEVA's ROE is +0.09%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, TEVA is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
TEVA vs EVO Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, EVO has a market cap of 504.4M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while EVO trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas EVO's P/E ratio is -2.01. In terms of profitability, TEVA's ROE is +0.09%, compared to EVO's ROE of -0.27%. Regarding short-term risk, TEVA is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check EVO's competition here
Evolus, Inc. (NASDAQ: EOLS)
TEVA vs EOLS Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, EOLS has a market cap of 486.1M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while EOLS trades at $7.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas EOLS's P/E ratio is -23.31. In terms of profitability, TEVA's ROE is +0.09%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, TEVA is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
TEVA vs AQST Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, AQST has a market cap of 480.7M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while AQST trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas AQST's P/E ratio is -5.89. In terms of profitability, TEVA's ROE is +0.09%, compared to AQST's ROE of +2.44%. Regarding short-term risk, TEVA is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check AQST's competition here
Kamada Ltd. (NASDAQ: KMDA)
TEVA vs KMDA Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, KMDA has a market cap of 439.1M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while KMDA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas KMDA's P/E ratio is 20.03. In terms of profitability, TEVA's ROE is +0.09%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, TEVA is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
TEVA vs TKNO Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, TKNO has a market cap of 365.1M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while TKNO trades at $6.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas TKNO's P/E ratio is -21.94. In terms of profitability, TEVA's ROE is +0.09%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, TEVA is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
TEVA vs TLRY Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, TLRY has a market cap of 338.8M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while TLRY trades at $3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas TLRY's P/E ratio is -2.16. In terms of profitability, TEVA's ROE is +0.09%, compared to TLRY's ROE of -0.09%. Regarding short-term risk, TEVA is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check TLRY's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
TEVA vs EBS Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, EBS has a market cap of 325.8M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while EBS trades at $6.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas EBS's P/E ratio is 4.41. In terms of profitability, TEVA's ROE is +0.09%, compared to EBS's ROE of -0.36%. Regarding short-term risk, TEVA is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check EBS's competition here
Canopy Growth Corporation (NASDAQ: CGC)
TEVA vs CGC Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, CGC has a market cap of 302.8M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while CGC trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas CGC's P/E ratio is -1.60. In terms of profitability, TEVA's ROE is +0.09%, compared to CGC's ROE of -0.33%. Regarding short-term risk, TEVA is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CGC's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
TEVA vs ALIM Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ALIM's P/E ratio is 5.28. In terms of profitability, TEVA's ROE is +0.09%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, TEVA is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
TEVA vs LNDC Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas LNDC's P/E ratio is -4.04. In terms of profitability, TEVA's ROE is +0.09%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, TEVA is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
TEVA vs ACB Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ACB has a market cap of 251.3M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ACB trades at $3.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ACB's P/E ratio is -2.87. In terms of profitability, TEVA's ROE is +0.09%, compared to ACB's ROE of -0.21%. Regarding short-term risk, TEVA is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ACB's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
TEVA vs LFCR Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, LFCR has a market cap of 242.4M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while LFCR trades at $6.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas LFCR's P/E ratio is -5.04. In terms of profitability, TEVA's ROE is +0.09%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, TEVA is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
TEVA vs TYHT Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas TYHT's P/E ratio is -1.61. In terms of profitability, TEVA's ROE is +0.09%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, TEVA is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
TEVA vs SIGA Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, SIGA has a market cap of 225.6M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while SIGA trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas SIGA's P/E ratio is 11.63. In terms of profitability, TEVA's ROE is +0.09%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, TEVA is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check SIGA's competition here
Glass House Brands Inc (NYSE: GLAS)
TEVA vs GLAS Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, GLAS has a market cap of 214.7M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while GLAS trades at $2.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas GLAS's P/E ratio is -4.36. In terms of profitability, TEVA's ROE is +0.09%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, TEVA is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check GLAS's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
TEVA vs REPH Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas REPH's P/E ratio is -8.04. In terms of profitability, TEVA's ROE is +0.09%, compared to REPH's ROE of -0.22%. Regarding short-term risk, TEVA is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check REPH's competition here
Theratechnologies Inc. (NASDAQ: THTX)
TEVA vs THTX Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas THTX's P/E ratio is -28.83. In terms of profitability, TEVA's ROE is +0.09%, compared to THTX's ROE of +0.36%. Regarding short-term risk, TEVA is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
TEVA vs ASRT Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ASRT's P/E ratio is -7.10. In terms of profitability, TEVA's ROE is +0.09%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, TEVA is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ASRT's competition here
Journey Medical Corporation (NASDAQ: DERM)
TEVA vs DERM Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, DERM has a market cap of 146.2M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while DERM trades at $5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas DERM's P/E ratio is -23.55. In terms of profitability, TEVA's ROE is +0.09%, compared to DERM's ROE of -0.20%. Regarding short-term risk, TEVA is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check DERM's competition here
Organigram Global Inc. (NASDAQ: OGI)
TEVA vs OGI Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, OGI has a market cap of 133.3M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while OGI trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas OGI's P/E ratio is 2.12. In terms of profitability, TEVA's ROE is +0.09%, compared to OGI's ROE of +0.21%. Regarding short-term risk, TEVA is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check OGI's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
TEVA vs CRDL Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, CRDL has a market cap of 132.7M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while CRDL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas CRDL's P/E ratio is -4.38. In terms of profitability, TEVA's ROE is +0.09%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, TEVA is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CRDL's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
TEVA vs ORGO Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ORGO has a market cap of 131.2M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ORGO trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ORGO's P/E ratio is 34.00. In terms of profitability, TEVA's ROE is +0.09%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, TEVA is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ORGO's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
TEVA vs SCTL Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas SCTL's P/E ratio is -7.86. In terms of profitability, TEVA's ROE is +0.09%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, TEVA is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
TEVA vs BGM Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, BGM has a market cap of 108.3M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while BGM trades at $8.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas BGM's P/E ratio is -1.78. In terms of profitability, TEVA's ROE is +0.09%, compared to BGM's ROE of -0.05%. Regarding short-term risk, TEVA is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
TEVA vs PROC Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas PROC's P/E ratio is 1.53. In terms of profitability, TEVA's ROE is +0.09%, compared to PROC's ROE of -2.22%. Regarding short-term risk, TEVA is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check PROC's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
TEVA vs CPIX Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, CPIX has a market cap of 100.7M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while CPIX trades at $6.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas CPIX's P/E ratio is -16.80. In terms of profitability, TEVA's ROE is +0.09%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, TEVA is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CPIX's competition here
OptiNose, Inc. (NASDAQ: OPTN)
TEVA vs OPTN Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas OPTN's P/E ratio is -4.42. In terms of profitability, TEVA's ROE is +0.09%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, TEVA is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
TEVA vs ZOM Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ZOM's P/E ratio is -1.62. In terms of profitability, TEVA's ROE is +0.09%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, TEVA is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
TEVA vs GRVI Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas GRVI's P/E ratio is 26.05. In terms of profitability, TEVA's ROE is +0.09%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, TEVA is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
TEVA vs ZYNE Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, TEVA's ROE is +0.09%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, TEVA is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ZYNE's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
TEVA vs ZYBT Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ZYBT has a market cap of 69.7M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ZYBT trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ZYBT's P/E ratio is -7.35. In terms of profitability, TEVA's ROE is +0.09%, compared to ZYBT's ROE of -0.31%. Regarding short-term risk, TEVA is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ZYBT's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
TEVA vs SSIC Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas SSIC's P/E ratio is 11.93. In terms of profitability, TEVA's ROE is +0.09%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, TEVA is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
TEVA vs VLNS Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas VLNS's P/E ratio is -1.03. In terms of profitability, TEVA's ROE is +0.09%, compared to VLNS's ROE of N/A. Regarding short-term risk, TEVA is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
TEVA vs DRRX Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas DRRX's P/E ratio is -4.44. In terms of profitability, TEVA's ROE is +0.09%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, TEVA is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
TEVA vs TLPH Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, TLPH has a market cap of 56.1M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while TLPH trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas TLPH's P/E ratio is -4.00. In terms of profitability, TEVA's ROE is +0.09%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, TEVA is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check TLPH's competition here
InterCure Ltd. (NASDAQ: INCR)
TEVA vs INCR Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, INCR has a market cap of 52.8M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while INCR trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas INCR's P/E ratio is -4.69. In terms of profitability, TEVA's ROE is +0.09%, compared to INCR's ROE of -0.09%. Regarding short-term risk, TEVA is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
TEVA vs JUPW Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas JUPW's P/E ratio is -2.41. In terms of profitability, TEVA's ROE is +0.09%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, TEVA is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
TEVA vs QLI Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas QLI's P/E ratio is -4.92. In terms of profitability, TEVA's ROE is +0.09%, compared to QLI's ROE of -0.16%. Regarding short-term risk, TEVA is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
TEVA vs HEXO Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas HEXO's P/E ratio is -0.26. In terms of profitability, TEVA's ROE is +0.09%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, TEVA is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
TEVA vs RMTI Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, RMTI has a market cap of 30.3M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while RMTI trades at $7.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas RMTI's P/E ratio is -5.61. In terms of profitability, TEVA's ROE is +0.09%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, TEVA is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check RMTI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
TEVA vs CPHI Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, CPHI has a market cap of 29.5M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while CPHI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas CPHI's P/E ratio is -1.59. In terms of profitability, TEVA's ROE is +0.09%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, TEVA is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CPHI's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
TEVA vs CYTH Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas CYTH's P/E ratio is -0.80. In terms of profitability, TEVA's ROE is +0.09%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, TEVA is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check CYTH's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
TEVA vs SHPH Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, SHPH has a market cap of 22.7M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while SHPH trades at $4.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas SHPH's P/E ratio is -0.22. In terms of profitability, TEVA's ROE is +0.09%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, TEVA is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check SHPH's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
TEVA vs TXMD Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, TXMD has a market cap of 21.5M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while TXMD trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas TXMD's P/E ratio is 94.83. In terms of profitability, TEVA's ROE is +0.09%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, TEVA is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
TEVA vs AYTU Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, AYTU has a market cap of 21.3M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while AYTU trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas AYTU's P/E ratio is -1.66. In terms of profitability, TEVA's ROE is +0.09%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, TEVA is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
TEVA vs EVOK Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas EVOK's P/E ratio is -7.97. In terms of profitability, TEVA's ROE is +0.09%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, TEVA is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
TEVA vs OPTH Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, OPTH has a market cap of 18.8M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while OPTH trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas OPTH's P/E ratio is -2.10. In terms of profitability, TEVA's ROE is +0.09%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, TEVA is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
TEVA vs ACRX Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ACRX's P/E ratio is -0.31. In terms of profitability, TEVA's ROE is +0.09%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, TEVA is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
TEVA vs CABR Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, CABR has a market cap of 10.9M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while CABR trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas CABR's P/E ratio is -1.54. In terms of profitability, TEVA's ROE is +0.09%, compared to CABR's ROE of -3.86%. Regarding short-term risk, TEVA is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
TEVA vs AGRX Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas AGRX's P/E ratio is -0.89. In terms of profitability, TEVA's ROE is +0.09%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, TEVA is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
TEVA vs NLTX Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas NLTX's P/E ratio is -0.28. In terms of profitability, TEVA's ROE is +0.09%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, TEVA is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check NLTX's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
TEVA vs INM Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, INM has a market cap of 7.6M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while INM trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas INM's P/E ratio is -0.45. In terms of profitability, TEVA's ROE is +0.09%, compared to INM's ROE of -1.35%. Regarding short-term risk, TEVA is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check INM's competition here
Lannett Company, Inc. (NYSE: LCI)
TEVA vs LCI Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas LCI's P/E ratio is -0.04. In terms of profitability, TEVA's ROE is +0.09%, compared to LCI's ROE of +1.66%. Regarding short-term risk, TEVA is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
TEVA vs ADMP Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ADMP's P/E ratio is -0.08. In terms of profitability, TEVA's ROE is +0.09%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, TEVA is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check ADMP's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
TEVA vs SNOA Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, SNOA has a market cap of 5.4M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while SNOA trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas SNOA's P/E ratio is -1.01. In terms of profitability, TEVA's ROE is +0.09%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, TEVA is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check SNOA's competition here
Mallinckrodt plc (AMEX: MNK)
TEVA vs MNK Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas MNK's P/E ratio is -0.44. In terms of profitability, TEVA's ROE is +0.09%, compared to MNK's ROE of -0.36%. Regarding short-term risk, TEVA is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
TEVA vs FLGC Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas FLGC's P/E ratio is -0.19. In terms of profitability, TEVA's ROE is +0.09%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, TEVA is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check FLGC's competition here
cbdMD, Inc. (AMEX: YCBD)
TEVA vs YCBD Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, YCBD has a market cap of 4M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while YCBD trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas YCBD's P/E ratio is -0.87. In terms of profitability, TEVA's ROE is +0.09%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, TEVA is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
TEVA vs GELS Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, GELS has a market cap of 3.9M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while GELS trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas GELS's P/E ratio is -0.98. In terms of profitability, TEVA's ROE is +0.09%, compared to GELS's ROE of -0.36%. Regarding short-term risk, TEVA is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check GELS's competition here
Akanda Corp. (NASDAQ: AKAN)
TEVA vs AKAN Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, AKAN has a market cap of 2.7M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while AKAN trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas AKAN's P/E ratio is -0.02. In terms of profitability, TEVA's ROE is +0.09%, compared to AKAN's ROE of +3.92%. Regarding short-term risk, TEVA is less volatile compared to AKAN. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check AKAN's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
TEVA vs PLXP Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas PLXP's P/E ratio is -0.22. In terms of profitability, TEVA's ROE is +0.09%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, TEVA is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check PLXP's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
TEVA vs UPC Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, UPC has a market cap of 2.5M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while UPC trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas UPC's P/E ratio is -0.48. In terms of profitability, TEVA's ROE is +0.09%, compared to UPC's ROE of -0.03%. Regarding short-term risk, TEVA is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for TEVA.Check UPC's competition here
Athenex, Inc. (NASDAQ: ATNX)
TEVA vs ATNX Comparison October 2026
Teva Pharmaceutical Industries Limited (NYSE: TEVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TEVA stands at 48.1B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, TEVA is priced at $41.31 on the NYSE, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TEVA currently has a P/E ratio of 14.09, whereas ATNX's P/E ratio is -0.02. In terms of profitability, TEVA's ROE is +0.09%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, TEVA is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for TEVA.Check ATNX's competition here